Resum
CD4+ T cell cytometry antedated the Human Immunodeficiency Virus (HIV) epidemic. However it was in the wake of the HIV scourge that CD4+ T cell counting technology gradually evolved from a pure cellular research assay technique into a routine clinical diagnostic test. In the more than two and half decades of the HIV/AIDS pandemic, this cell based diagnostic test has undergone several phases of technological improvements in the efforts to produce cheaper and more robust equipment for the monitoring of patients. The evolution however, is still very much in progress. Resource poor countries that remain the worst hit by the scourge of HIV/AIDS are paradoxically usually the last to benefit from the impact of the technological advancements in CD4+ T cell cytometry. This review highlights the progress and the scientific milestones so far attained in the development of improved techniques for CD4+ T cells count as a major cornerstone of patient care, as well as the emerging future directions in the evolution of this important cellular diagnostic test. Some of the challenges for developing economies are highlighted.
Keywords: CD4+ T cell cytometry; evolving technology; resource poor settings.
Résumé
La cytometrie des cellules CD4+ de l’épidémie du virus immuno-déficient acquis (VIH) est devenue graduellement une technique de recherche routinière de diagnostic clinique.il y a plus de vingt ans la pandémie du VIH/SIDA, ce test de diagnostic de cellules a suivi plusieurs phases d’évolution technologiques dans les efforts de produire un équipement robuste et moins couteux pour l’évaluation et suivi des patients. Cette évolution cependant est encore en progrès. Les pays sous-développés demeurent les plus touchées par la pandémie du VIH/SIDA, sont paradoxalement les derniers a bénéficier de l’impact des avancées technologiques dans la cytometrie des cellules T de type CD4+. Cette revue illumine les progrès scientifiques achevés dans l’amélioration des développements technologiques pour la détermination du tau des CD4+, important paramètre dans les soins des patients. Aussi bien que les directions futures dans l’évolution du test de diagnostic cellulaire, Certains défis pour les économies émergeant sont illuminés.
Correspondence: Dr. O.P. Arewa, Department of Haematology and Immunology, College of Health Sciences, Niger Delta University, Wilberforce Island Bayelsa State, Nigeria.
Referències
Philips AN, Lee CA, Elford J, Janossy G, Timms A, Bofill M et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991; 337:389-392.
Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy induced suppression of human immunodeficiency virus load. J infect Dis 1999; 180: 530-533.
McAnulty JM, Modessit SK, Yusem SH, Hyer CJ and Flemming DW. Improved AIDS surveillance through laboratory-initiated CD4 cell count reporting. J Acquir Immune Defic Syndr Human Retrovirol. 1997; 16: 362-366.
Peter T, Badrichani A, Wu E, Freeman R, Ncube B, Ariki F et al. Challenges in implementing CD4 testing in resource-limited settings. Cytometry Part B 2008; 74B (Suppl. 1): S123-S130.
Bentwich Z (2005) CD4 Measurements in Patients with HIV: Are They Feasible for Poor Settings? PLoS Med 2005; 2(7): e214
Pattanapanyasat K, Sukapirom K and Kowawisatsut L, Thepthai C. New BD FACScount TM CD4 reagent system for simultaneous enumeration of percent and absolute CD4 T-lymphocytes in HIV-1 infected paediatric patients. Cytometry Part B 2008; 74B(Suppl. 1): S98-S106, 2008.
Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men; Evidence of a new acquired cellular immunodeficiency. N E J Med 1981:1425-1431.
Taylor JM, Fahey JL, Detels R and Giorgi JV, CD4 percentage, CD4 number and CD4:CD8 ratio in HIV infection: Which to use and how to use. J Acquir Immune Defic Syndr 1989; 2:114-124.
Mandy F, Nicholson J, Autran B and Janossy G. T cell subset counting and the fight against AIDS: Reflections over a 20 year struggle. Cytometry 2002; 50: 39-45.
Mellors JW, Rinaldo CR, Gupta G, White RM, Todd JA and Kingsley IA. Prognosis in HIV 1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
O’Shea S, Rostron T, Hamblin AS, Palmer SJ and Banatvala JE. Quantitation of HIV: Correlation with clinical, virological, and immunological status. J Med Vir 1991; 35:65-69.
US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. www.aidsinfo.nih.gov Accessed September 25, 2008.
Mandy F, Janossy G, Bergeron M, Pilon R and Faucher S. Affordable T cell Enumeration for Resource-Limited regions; A status report for 2008. Cytometry Part B 2008; 74B (Suppl. 1): S27-S39.
Centre for Disease Control and Prevention. Revised guidelines for performing CD4 T cell determinations in persons infected with human immunodeficiency virus (HIV). MMWR 1997; 46:1-29.
Strauss K, Hannet I, Engels S, Shiba A, Ward DM, Uley S et al. Performance evaluation of the FACScount system: A dedicated system for clinical cellular analysis. Cytometry 1996; 26: 52-59.
Brando B, Scarpati B and D’Anvazo G. Development of simplified, inexpensive flow cytometry for CD4+ T cell counting. www.Affordcd4.com. Accessed 23rd Oct. 2008.
Barbesti S, Soldini L, Carcelain G, Giugnet A, Colizzi V and Mantelli B. A simplified flow cytometry method of CD4 and CD8 cell counting based on thermoresistant reagents: implications for large scale monitoring of HIV-infected patients in resource-limited settings. Cytometry B Clin Cytom. 2005 Nov;68(1):43-51.
Manian BS. Affordable diagnostics—changing the paradigm in India. Cytometry B. Clin Cytom. 2008; 74 Suppl 1:S117-122.
Shapiro HM and Perlmutter NG. ‘Killer’ applications: Towards affordable rapid cell based diagnostics for malaria and tuberculosis. Cytometry Part B 2008; 74B (Suppl.1).
Rodriguez WR, Christodoulides N, Floriano PN, Graham S, Mohanty S, et al. A microchip CD4 counting method for HIV monitoring in resource-poor settings. PLoS Med 2: (2005) e182. www.plos.org Accessed 20th 2008.
Bentwich Z. CD4 Measurements in Patients with HIV: Are They Feasible for Poor Settings? PLoS Med 2(7): (2005) e214 . www.plos.org Accessed 20th 2008.
Willis RC. Sorting out the mess. Researchers are using a variety of methods to isolate specific cell types. Modern Drug Discovery. Nov. 2004 Vol. 7 (11):29-32.
Mahajan AP, Hogan JW, Snyder B, Kumarasamy N, Mehta K Solomon S et al. Changes in total lymphocyte count as a surrogate for changes in CD4 count following initiation of HAART: implications for monitoring in resource-limited settings. J Acquir Immune Defic Syndr. 2004 May.1; 36(1):567-575.
Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS. 2003 Mar 7; 17(4):541-545.
Akinola NO, Olasode O, Adediran IA, Onayemi O, Muraina A, Irinoye et al. The search for a predictor of CD4 cell count continues: total lymphocyte count is not a substitute for CD4 cell count in the management of HIV-infected individuals in a resource-limited setting. Clin Infect Dis. 2004. Aug 15;39(4):579-581.
Gupta A, Gupte N, Bhosale R, Kakrani A, Kulkarni V, Nayak U et al. Low sensitivity of total lymphocyte count as a surrogate marker to identify antepartum and postpartum Indian women who require antiretroviral therapy. J Acquir Immune Defic Syn. Nov 2007. 1; 46(3):338-342.
WHO/UNAIDS. Emergency scale-up of antiretroviral therapy in resource limited settings: Technical and operational recommendations to achieve 3 by 5. Geneva, Switzerland: World Health Organization; 2004. p 41.